NASDAQ · Drug Manufacturers - Specialty & Generic
IRWD (IRWD) Stock
$4.29
+0.82%
NASDAQ: IRWD
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?
Zacks · Jul 8, 2026
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
Zacks · Jul 8, 2026
Ironwood Pharmaceuticals (IRWD) Gains From Strong Fiscal Q1 2026 Earnings Momentum
Insider Monkey · Jul 3, 2026
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Zacks · Jun 26, 2026
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Zacks · Jun 25, 2026
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About IRWD
IRWD is led by CEO Thomas A. McCourt, employs 253 people, headquartered in US, publicly traded since 2010.
IRWD stock trades at $4.29 with a market capitalization of $705.37M. The stock is valued at a price-to-earnings (P/E) ratio of 5.39, price-to-book of -4.39, price-to-sales of 1.81. Over the past 52 weeks the stock has ranged between $1.01 and $5.78, and currently trades 25.8% below its 52-week high.
On profitability, IRWD generates a return on equity (ROE) of -57.40%, return on capital employed of 93.58%, an operating margin of 40.20%, a net profit margin of 33.36%.